Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial of Low-Dose Arginine Butyrate and Ganciclovir/Valganciclovir in EBV(+)Lymphoid Malignancies

NCT00917826 is registered in ClinicalTrials.gov with HemaQuest Pharmaceuticals Inc. as lead sponsor.

NCT NCT00917826
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00917826 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial of Low-Dose Arginine Butyrate and Ganciclovir/Valganciclovir in EBV(+)Lymphoid Malignancies
Lead sponsor
HemaQuest Pharmaceuticals Inc.
Phase
Phase 2
Overall status
Terminated
Start date
September 30, 2008
Completion date
Not reported
Enrollment
1 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ebv lymphomas, lympho-proliferative diseases